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Introduction: TSU-68 is an oral small-molecule inhibitor that
targets vascular endothelial growth factor receptor 2, platelet-de-
rived growth factor receptor , and fibroblast growth factor receptor
1. An open-label, single-arm, phase I study was performed to evaluate
escalating doses of TSU-68 in combination with standard chemother-
apy in patients with advanced non-small cell lung cancer.
Methods: Eligible patients received TSU-68 at 200 or 400 mg twice
daily and continuously in combination with carboplatin (area under the
curve, 6mg  min/mL) plus paclitaxel (200mg/m2) on day 1 every 21 days.
Results: Thirty-seven patients were enrolled at the two dose levels
of TSU-68. No dose-limiting toxicities were observed with TSU-68
at the 200 mg twice a day dose level. At 400 mg twice a day, one of
six patients experienced a dose-limiting toxicity (anorexia of grade
3) during the first cycle. The 400 mg twice a day dose level was
determined to be the recommended dose, and a total of 34 patients
were treated at this dose. Overall, adverse events were mild to
moderate in severity, with the most frequently observed such events
being myelosuppression, neuropathy, and gastrointestinal disorders.
No drug-related bleeding was observed. The objective response rate
was 39.4% (95% confidence interval, 22.9–57.9%), and median pro-
gression-free survival was 5.6 months (95% confidence interval, 3.6–
7.2 months). Coadministration of TSU-68, carboplatin, and paclitaxel
had no substantial impact on the pharmacokinetics of these drugs.
Conclusions: TSU-68 can be safely combined with standard doses
of carboplatin-paclitaxel, with the combination manifesting promis-
ing antitumor activity.
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Lung cancer is the leading cause of death related to cancerworldwide, with non-small cell lung cancer (NSCLC)
accounting for 85% of lung cancer cases.1 For individuals
with advanced or metastatic NSCLC, platinum-based chemo-
therapy is the mainstay of first-line treatment on the basis of
the moderate improvement in survival and quality of life it
affords compared with best supportive care alone.2 There is
thus still a need for new treatment regimens to improve the
outcome for patients with advanced NSCLC.
Angiogenesis, the formation of new blood vessels from
a preexisting vasculature, is essential for tumor growth and
metastasis.3,4 Receptor tyrosine kinases, including vascular
endothelial growth factor receptors (VEGFRs), platelet-de-
rived growth factor receptors (PDGFRs), and fibroblast
growth factor receptors (FGFRs), together with their corre-
sponding ligands, play key roles in angiogenesis.3,4 The
addition of bevacizumab, a monoclonal antibody specific for
VEGF, to carboplatin-paclitaxel was shown to result in a
2-month increase in median overall survival in individuals
with advanced nonsquamous NSCLC.5 In a confirmatory
study, the addition of bevacizumab to cisplatin-gemcitabine
resulted in a significant improvement in progression-free
survival (PFS), but the overall survival benefit did not
achieve statistical significance.6,7 These observations provide
a rationale for combining an angiogenesis inhibitor with
conventional cytotoxic chemotherapy in individuals with ad-
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vanced NSCLC, although the application of such a combina-
tion is currently limited by the risk of life-threatening hemop-
tysis and is not indicated in patients with squamous cell
histology.5
TSU-68 (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan)
is an orally available, small-molecule inhibitor that targets
VEGFR2, PDGFR, and FGFR1.8,9 TSU-68 has been shown
to inhibit the growth of and to reduce vessel density in human
tumor xenografts subcutaneously implanted in nude mice.9–12
Additional preclinical data suggest that the effect of TSU-68
on vascular endothelial cells is enhanced in combination with
paclitaxel, resulting in greater antitumor activity than that
observed with either agent alone.13 Phase I studies of TSU-68
monotherapy in patients with advanced and heavily pre-
treated malignancies have determined the recommended dose
(RD) to be up to 400 mg twice daily administered orally and
continuously, with the most frequently encountered adverse
events (AEs) being mild gastrointestinal toxicities such as
anorexia and diarrhea.14,15 We now describe a phase I study
of TSU-68 in combination with standard carboplatin-pacli-
taxel chemotherapy as first-line treatment for patients with
advanced NSCLC.
PATIENTS AND METHODS
Patients
Eligible patients met the following criteria: a diagnosis
of NSCLC confirmed either histologically or cytologically, a
clinical stage of IIIB not amenable to curative treatment or of
stage IV, no previous chemotherapy (prior adjuvant chemo-
therapy was permitted if completed 180 days before enroll-
ment), an age of 20 to 74 years, an Eastern Cooperative
Oncology Group performance status of 0 or 1, a projected life
expectancy of at least 3 months, and adequate hematologic,
hepatic, and renal function. Patients were excluded if they
had symptomatic brain metastasis, a history of drug allergy,
malignant ascites requiring drainage, treatment with any
investigational drug within 4 weeks before study enrollment,
or severe medical conditions such as uncontrolled hyperten-
sion, myocardial infarction, unstable angina pectoris, or in-
fection with fever. Pregnant or breast-feeding women were
also excluded. All patients provided written informed consent
to participate in the study, which was conducted in accor-
dance with good clinical practice guidelines and was ap-
proved by the Institutional Review Board of each center.
Study Design and Treatment
This was an open-label phase I study of TSU-68 in
combination with carboplatin and paclitaxel in chemotherapy-
naive patients with advanced NSCLC. The study consisted of
two steps. The objectives of the first, dose-escalation step
were to determine the RD of TSU-68 in this regimen and
pharmacokinetics. If a dose-limiting toxicity (DLT) was not
observed in any of the first three patients, the dose was
escalated to the next level. If a DLT was observed in one of
the first three patients, three additional patients were recruited
to that dose level. If fewer than two of the first six patients
experienced a DLT in the first cycle, the dose level was to be
recommended for the second step. The primary objective of
the second step was to evaluate treatment feasibility at the RD
by determining the proportion of patients who received more
than 50% of the planned dose of TSU-68 within the first three
cycles. The sample size at the RD was determined to be 30
with a one-sided alpha of 2.5% and a power of 90%; the
expected and threshold values were 66.7 and 33.3%.
Patients were premedicated before intravenous pacli-
taxel administration for 3 hours at a dose of 200 mg/m2
followed by intravenous administration of carboplatin for 1
hour at an area under the curve (AUC) of 6 mg  min/mL on
day 1 of each 3-week cycle. TSU-68 was administered orally
twice daily at either 200 or 400 mg for 21 consecutive days.
Patients who discontinued the chemotherapy could continue
treatment with TSU-68 alone until disease progression or the
development of unacceptable toxicity.
Safety and Efficacy Assessment
Patients were evaluated for AEs during therapy and for
28 days after administration of the last dose of the study
treatment. Toxicity was evaluated according to the National
Cancer Institute Common Toxicity Criteria version 3. A DLT
was defined as any of the following adverse drug reactions:
neutropenia of grade 4 for 7 days, thrombocytopenia of
grade 4, febrile neutropenia, or a nonhematologic toxicity of
grade 3 with the exception of diarrhea, nausea, vomiting,
hyponatremia, or hypokalemia, each of grade 3.
Antitumor activity was assessed radiologically (com-
puted tomography or magnetic resonance imaging) every 6
weeks. All responses were defined according to the RECIST
1.0.16 If a patient was documented as having a complete
response (CR) or a partial response (PR), a confirmatory
evaluation was performed after an interval of 4 weeks. Dis-
ease control was defined as the best tumor response among
CR, PR, or stable disease (SD) that was confirmed and
sustained for 6 weeks or longer. PFS was defined as the time
from the date of registration to the date of the detection of
progressive disease or of death from any cause, and it was
assessed by the Kaplan-Meier method.
Pharmacokinetics
Pharmacokinetics were analyzed during the first cycle
of treatment in nine patients enrolled in the first step. Blood
samples were sequentially collected until 11 hours after the
first dose on days 1 and 2 for TSU-68, 24 hours after infusion
for carboplatin, and 48 hours after infusion for paclitaxel. The
concentrations of TSU-68, carboplatin-derived free platinum,
and paclitaxel in plasma were determined by validated bio-
analytic methods. The following pharmacokinetic parameters
were calculated from the plasma concentration data by non-
compartment analysis: maximum plasma concentration (Cmax),
time of Cmax (tmax), terminal half-life (t1/2), and AUC for
TSU-68 and total clearance (CLtot), and distribution volume at
steady state (Vdss) for carboplatin and paclitaxel.
Assessment of Biomarkers
Blood samples were collected from patients at baseline
and after each cycle of TSU-68 treatment in combination with
carboplatin-paclitaxel, and plasma was isolated and stored at
70°C until analysis. The concentrations of VEGF-A,
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VEGF-C, soluble VEGFR2, E-selectin, PDGF-AA, PDGF-BB,
acidic FGF, and basic FGF were quantified with the use of
enzyme-linked immunosorbent assay kits (R&D Systems,
Minneapolis, MN). All samples were analyzed in dupli-
cate. Changes in biomarker concentrations from baseline
were evaluated with the exact paired Wilcoxon test (two-
sided). A p value of 0.05 was considered statistically
significant.
RESULTS
Patient Characteristics
Thirty-seven patients were enrolled at seven clinical sites
in Japan between February and October 2009. Characteristics of
the 37 enrolled subjects are summarized in Table 1. Twenty-one
patients were male and 16 were female. The median age was 64
years (range, 42–74 years). The most common histology was
adenocarcinoma (29 patients, or 78.4%), followed by squamous
cell carcinoma (5 patients, or 13.5%); three patients who had
unspecified NSCLCs were classified as “other.”
Dose Escalation and DLTs
No DLT was observed in the first three patients treated
with 200 mg of TSU-68 twice daily and so the dose was
escalated to the second level of 400 mg twice daily. Given
that one of the first three patients experienced a DLT (an-
orexia of grade 3) at 400 mg of TSU-68 twice daily, three
additional patients were accrued. None of these additional
patients developed a DLT, and the dose of 400 mg of TSU-68
twice daily was therefore determined as the RD.
Drug Delivery
A total of 34 patients were treated with 400 mg of
TSU-68 twice daily combined with paclitaxel at 200 mg/m2
and carboplatin at an AUC of 6 mg  min/mL. The median
number of cycles of carboplatin-paclitaxel delivered was 3
(range, 1–6). The median relative dose intensities were
83.7% for paclitaxel and 92.4% for carboplatin, with dose
reductions for these drugs often being a result of neuropathy.
Thirty-two patients (94.1%) received more than 50% of the
planned TSU-68 dose within the first three cycles, achieving
the defined criterion of treatment feasibility. The median
FIGURE 1. Patient disposition.
ALT, alanine aminotransferase; AST,
asparate aminotransferase.
TABLE 1. Characteristics of the Study Patients (n  37)
Parameter No. Percentage
Sex
Male 21 56.8
Female 16 43.2
Age (yr)
Median 64.0
Range 42–74
Stage
IIIB 5 13.5
IV 28 75.7
Recurrent 4 10.8
Histology
Adenocarcinoma 29 78.4
Squamous 5 13.5
Other 3 8.1
ECOG performance status
0 14 37.8
1 23 62.2
ECOG, Eastern Cooperative Oncology Group.
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duration of treatment with TSU-68 was 3 cycles (range,
1–18), with the median relative dose intensity being 75.9%.
Eleven patients treated with TSU-68 at 400 mg twice daily
had the dose reduced to 200 mg after a median of 2 cycles
(range, 1–6): two each because of the development of throm-
bocytopenia of grade 4 or anorexia of grade 3, and one each
because of hyponatremia of grade 4; an increase in alanine
aminotransferase (ALT), diarrhea, pericarditis, fatigue, hy-
perkalemia, or febrile neutropenia of grade 3; or cholecystitis
of grade 2.
Patient disposition is shown in Figure 1. Out of 34
patients, 19 individuals discontinued treatment before com-
pletion of combination therapy, most as a result of disease
progression (six patients) or AEs (nine patients; four with
neuropathy and one each with neuropathy and myalgia, with
leukopenia, with pericarditis and pericardial effusion, or
with an increase in aspartate aminotransferase or ALT). Fifteen
patients completed four to six cycles of the combination therapy.
The study treatment was discontinued in six of these patients
because of disease progression (two patients) or AEs (four
patients; two with leukopenia and neutropenia and one each with
neuropathy or fatigue). The other nine patients continued
TSU-68 monotherapy in a maintenance setting. TSU-68 was
subsequently discontinued in eight of these nine patients because
of disease progression and in the remaining patient because of an
AE (infection of grade 2). No dose reductions of TSU-68 were
implemented during maintenance therapy, which had a median
duration of four cycles (range, 1–14).
Toxicity
The major AEs during the entire treatment period at the
RD are shown in Table 2. The hematologic AEs of grade 3
included neutropenia (grade 3 in 35% of patients and grade 4
in 38%), anemia (grade 3 in 32% and grade 4 in 3%),
thrombocytopenia (grade 3 in 24% and grade 4 in 9%), and
leukopenia (grade 3 in 15% and grade 4 in 3%). Nonhema-
tologic toxicities of grade 3 included neuropathy (9%), an-
orexia (15%), fatigue (6%), diarrhea (6%), and arthralgia,
elevation of ALT or aspartate aminotransferase, edema (head
and neck, or limb), and febrile neutropenia (each at 3%). No
nonhematologic toxicities of grade 4 were observed, and
there were also no treatment-related deaths.
Pharmacokinetics
Pharmacokinetic analysis of TSU-68, at doses of 200
mg (n  3) and 400 mg (n  6), in the presence of paclitaxel
and carboplatin was performed in nine subjects. The in-
creases in Cmax and AUC for TSU-68 at level 2 (400 mg) on
day 1 compared with those at level 1 (200 mg) were consis-
tent with the increase in TSU-68 dosing (Table 3). At both
doses, the plasma concentration of TSU-68 achieved Cmax at
3 to 4 hours and then declined at a first-order rate (Figure 2).
The Cmax and AUC after repeated administration of TSU-68
on day 2 were lower than those after the first administration
on day 1 (Figure 2, Table 3). The values for these pharma-
cokinetic parameters of TSU-68 administered with paclitaxel
and carboplatin in this study are similar to those previously
obtained for single-agent dosing of TSU-68. Pharmacokinetic
analysis of paclitaxel and carboplatin-derived free platinum
revealed that Cmax, AUC, t1/2, and Vdss did not differ sub-
stantially between the two dose levels of TSU-68 (Table 3).
Biomarker Analysis
We investigated changes in blood biomarkers during
treatment with TSU-68. The mean plasma levels of VEGF-C
and E-selectin decreased significantly by 40 and 33%, respec-
tively, from baseline levels over three cycles of treatment
(p  0.001) (Figure 3). The plasma concentration of soluble
VEGFR2 also decreased by 13% from baseline after four
cycles of treatment (p  0.05). In contrast, the plasma levels
of VEGF-A, PDGF-AA, PDGF-BB, acidic FGF, and basic
FGF remained unchanged throughout treatment.
Antitumor Activity
A total of 33 of the 34 patients treated with 400 mg of
TSU-68 twice daily combined with paclitaxel and carboplatin
were assessable for response; the remaining patient was not
available for measurement of target lesions. For the 33
assessable patients, there were 13 PRs and no CRs, yielding
an overall response rate of 39.4% (95% confidence interval
[CI], 22.9–57.9%). Thirteen patients (39.4%) had SD, yield-
ing an overall disease control rate (CR PR SD) of 78.8%
(95% CI, 61.1–91.0%). A waterfall plot revealed that most
patients showed a decrease in the size of their target lesions
(Figure 4). Median PFS was 5.6 months (95% CI, 3.6–7.2
months).
TABLE 2. Adverse Events for 34 of the Study Patients
Toxicity
Grade
Total
(%)
Grade
3/4 (%)1 2 3 4
Hematologic
Hemoglobin 6 14 11 1 94.1 35.3
Neutrophils 0 4 12 13 85.3 73.5
Platelets 10 5 8 3 76.5 32.4
Leukocytes 6 12 5 1 70.6 17.6
Nonhematologic
Neuropathy
sensory
14 15 3 0 94.1 8.8
Alopecia 19 12 0 0 91.2 0
Anorexia 13 9 5 0 79.4 14.7
Nausea 13 14 0 0 79.4 0
Arthralgia 14 10 1 0 73.5 2.9
Fatigue 9 12 2 0 67.6 5.9
Diarrhea 11 9 2 0 64.7 5.9
Vomiting 12 9 0 0 61.8 0
Proteinuria 13 7 0 0 58.8 0
Myalgia 12 7 0 0 55.9 0
Edema: head
and neck
12 0 1 0 38.2 2.9
ALT 9 2 1 0 35.3 2.9
AST 6 2 1 0 26.5 2.9
Edema: limb 4 1 1 0 17.6 2.9
Hypertension 3 4 0 0 20.6 0
Febrile
neutropenia
0 0 1 0 2.9 2.9
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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FIGURE 2. Time course of the
plasma concentration of TSU-68
after administration of the first (day
1) or third (day 2) dose of the drug
at 200 or 400 mg. Carboplatin and
paclitaxel were coadministered on
day 1. Data were presented as
means  SD.
FIGURE 3. Changes in the plasma
concentrations of biomarkers dur-
ing treatment with TSU-68 in com-
bination with carboplatin-paclitaxel
chemotherapy. The plasma levels
of VEGF-C and E-selectin were
measured at baseline and after ad-
ministration of three cycles of treat-
ment for 19 patients. p values were
determined with the paired exact
Wilcoxon test (unadjusted).
TABLE 3. Pharmacokinetic Parameters of TSU-68, Carboplatin (Free Platinum), and Paclitaxel After Drug Coadministration
(a) TSU-68
Level tmax (h) Cmax (g/mL) AUC0-last (g  h/mL) t1/2 (h)
1
Day 1 3.0  0.9 8.7  0.9 42.5  15.6 3.7  0.5
Day 2 2.5  1.5 6.1  1.3 25.6  6.3 3.2  0.3
2
Day 1 3.8  1.0 14.6  7.5 76.3  35.9 2.4  0.4
Day 2 3.2  2.0 7.0  3.0 35.6  13.3 2.2  0.8
(b) Carboplatin (Free Platinum)
Level tmax (h) Cmax (g/mL) AUC0-last (mg  min/mL) AUC0–inf (mg  min/mL) t1/2 (h) CLtot (mL/min) Vdss (L)
1 1.0  0.1 24.9  4.8 4.12  0.59 4.14  0.59 3.9  0.1 86.9  16.3 15.8  3.6
2 1.0  0.1 24.5  6.7 3.94  0.62 3.98  0.64 4.1  0.4 96.1  30.8 17.1  2.6
(c) Paclitaxel
Level tmax (h) Cmax (g/mL) AUC0–inf (g  h/mL) AUC0–inf (g  h/mL) t1/2 (h) CLtot (mL min
1 m2) Vdss (L/m
2)
1 3.1  0.1 6.50  0.76 23.0  1.7 23.3  1.6 10.9  0.7 143  10 41.1  11.0
2 3.1  0.1 9.95  3.33 29.9  7.2 30.3  7.2 10.7  1.2 115  25 33.6  7.9
Data are presented as means  SD (level 1, n  3; level 2, n  6).
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DISCUSSION
Our phase I study was designed to evaluate the feasi-
bility of daily administration of TSU-68 in combination with
paclitaxel and carboplatin and thereby to identify a regimen
suitable for further phase II and III evaluation in chemother-
apy-naive individuals with advanced NSCLC. According to
the criteria defined in our study, TSU-68 at a dose of 400 mg
twice daily can be integrated with the combination of pacli-
taxel and carboplatin. Given that a previous phase I study
established 400 mg twice daily as an appropriate dose for
treatment with TSU-68 as a single agent,14 further dose-
escalation evaluation of this drug was not pursued. The AEs
observed in this study were predictable from the safety
profiles of TSU-68, carboplatin, and paclitaxel. Although
there are limitations to comparisons of the results from
different studies, the addition of TSU-68 to carboplatin and
paclitaxel seems to increase the frequency and severity of
thrombocytopenia and anemia compared with those previ-
ously observed with similar doses of carboplatin and pacli-
taxel.5,17,18 With regard to nonhematologic toxicities, TSU-68
may increase the frequency of neuropathy and gastrointesti-
nal conditions (diarrhea and nausea); however, most of these
toxicities were of grade 1 or 2 and were manageable with
standard supportive treatment. Other toxicities attributed to
carboplatin-paclitaxel chemotherapy did not occur in this
study at a greater rate or severity than expected. In contrast to
other VEGFR tyrosine kinase inhibitors, no hand-foot syn-
drome and only a low frequency of hypertension were ob-
served in the present trial, consistent with the safety data from
other TSU-68 studies.14,15 Importantly, none of the patients
enrolled in this study, including those with squamous cell
carcinoma, showed any bleeding events irrespective of relat-
edness. The small sample size of 37 patients treated with
TSU-68 in this study makes it difficult to conclude whether
the absence of life-threatening hemoptysis was attributable to
chance. However, unlike bevacizumab, TSU-68 combined
with carboplatin-paclitaxel seems to be safe for patients with
all histological types of NSCLC.
The pharmacokinetics of TSU-68 administered with
carboplatin and paclitaxel were found to be similar to those
previously described for monotherapy.14 The repeated admin-
istration of TSU-68 decreased its plasma exposure, as has
been consistently observed in previous trials, possibly as a
result of autoinduction of TSU-68 metabolism.14,15,19 The
pharmacokinetic parameters of carboplatin and paclitaxel did
not differ substantially between the two tested doses of
TSU-68. The pharmacokinetic parameters of paclitaxel and
carboplatin in this study were similar to those previously
described for respective single-agent administration.20–22 To-
gether, our pharmacokinetic data suggest that concomitant
administration of TSU-68, carboplatin, and paclitaxel accord-
ing to the adopted treatment schedule had no marked impact
on the pharmacokinetics of any of the three drugs, although
further well-designed pharmacokinetic studies will be neces-
sary to accurately evaluate drug-drug interactions.
Evaluation of novel targeted agents is facilitated by the
identification of biomarkers of biologic activity. E-selectin is
an endothelial cell-specific membrane glycoprotein that par-
ticipates in leukocyte adhesion and has also been suggested to
function in angiogenesis.23,24 VEGF-C, which is one of the
ligands of VEGFR2 and VEGFR3, is active in angiogenesis
and lymphangiogenesis.25 We observed decreases in the
plasma concentrations of E-selectin, VEGF-C, and soluble
VEGFR2 associated with TSU-68 treatment, with similar
findings having been described for other VEGF signaling
inhibitors.26–28 These observations may be related to the
pronounced antiangiogenic activity of TSU-68 previously
demonstrated in preclinical studies,8,9 although the mecha-
nism responsible for these effects remains unclear. Given that
TSU-68 also inhibits PDGFR and FGFR as well as VEGFR,
we also determined the plasma concentrations of PDGF-AA,
PDGF-BB, acidic FGF, and basic FGF. However, there were
no marked changes in the concentrations of these growth
factors during TSU-68 treatment. Further attempts to identify
potential biomarkers associated with inhibition of PDGFR
and FGFR are warranted.
Although tumor evaluation was not the primary objec-
tive of our study, we found the chosen drug combination to be
active, with a response rate of 39.4%, disease control rate of
78.8%, and median PFS of 5.6 months. These efficacy data
compare favorably with those obtained in previous phase III
studies of carboplatin and paclitaxel for chemonaive patients
with advanced NSCLC,5,17,18 suggesting that TSU-68 may
augment the antitumor effects of chemotherapy.
In conclusion, administration of TSU-68 at 400 mg
twice daily can be combined with a standard regimen of
carboplatin-paclitaxel, without relevant pharmacokinetic in-
teractions, in chemonaive patients with advanced NSCLC.
The observed antitumor activity was encouraging, with most
patients treated at the RD showing some degree of tumor
shrinkage. Further studies of this triple-drug combination in
patients with advanced NSCLC of any histology are thus
warranted.
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